<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691064</url>
  </required_header>
  <id_info>
    <org_study_id>A-LUT-T-E02-402</org_study_id>
    <nct_id>NCT03691064</nct_id>
  </id_info>
  <brief_title>Post-Authorization Long-Term Safety Study of LUTATHERA</brief_title>
  <acronym>SALUS</acronym>
  <official_title>International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Accelerator Applications</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Accelerator Applications</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the incidence and nature of potential long-term safety outcomes (follow-up period
      up to 7 years) in patients with unresectable or metastatic, well-differentiated, somatostatin
      receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and
      prospective data will be used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>secondary cancers: incidence of secondary cancers</measure>
    <time_frame>up to 7 years follow-up</time_frame>
    <description>incidence of secondary cancers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety profile: incidence of adverse events</measure>
    <time_frame>up to 7 years follow-up</time_frame>
    <description>incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>up to 7 years follow-up</time_frame>
    <description>mortality (all cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LUTATHERA dose per administration</measure>
    <time_frame>completion of treatment phase (approximately 2 years total)</time_frame>
    <description>average dose per administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LUTATHERA total dose</measure>
    <time_frame>completion of treatment phase (approximately 2 years total)</time_frame>
    <description>average total dose administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LUTATHERA number of administrations</measure>
    <time_frame>completion of treatment phase (approximately 2 years total)</time_frame>
    <description>average number of LUTATHERA doses</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>LUTATHERA</arm_group_label>
    <description>Treated per labeled LUTATHERA dosing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUTATHERA</intervention_name>
    <description>Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 microCurie [mCi]) every 8 weeks for a total of 4 doses.</description>
    <arm_group_label>LUTATHERA</arm_group_label>
    <other_name>Lu 177 dotatate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients treated with LUTATHERA for the labeled indication using the approved dosing
        regimen.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with unresectable or metastatic, well-differentiated, somatostatin receptor
             positive gastroenteropancreatic neuroendocrine tumours treated with LUTATHERA

        Exclusion Criteria:

          -  hypersensitivity to LUTATHERA (active substance or any of the excipients)

          -  pregnancy (established, suspected, or when not excluded)

          -  kidney failure with creatinine clearance &lt; 30 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Advanced Accelerator Applications</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Santoro, Ph.D.</last_name>
    <phone>917-854-1313</phone>
    <email>paola.santoro@adacap.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97339</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Mittra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason in Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagen Kennecke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitario de Coimbra, E.P.E.</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gracinda Costa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar et Universitario de Coimbra EPE</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gracinda Costa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B152WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tahir Shah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tahir Shah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QC</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Casey</last_name>
      <phone>44 01223 217145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sobhan Vinjamuri, MD MS MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW32QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaunak Navalkissoor, MSc, MBChB</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys Hospital Nuclear Medicine Department</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Lewington, BM MSc FRCP FRCR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajaventhan Srirajaskanthan, MD MD BS BSc MRCP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital (Imperial)</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rohini Sharma, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroenteropancreatic neuroendocrine tumours</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

